Article
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.
Journal of viral hepatitis - 1 May 2020
Poordad Fred, Castro RuiSarmento E, Asatryan Armen, Aguilar Humberto, Cacoub Patrice, Dieterich Douglas, Marinho Rui Tato, Carvalho Armando, Siddique Asma, Hu Yiran Bonnie, Charafeddine Mariem, Bondin Mark, Khan Nader, Cohen Daniel E, Felizarta Franco
Abstract excerpt
The 3-DAA regimen consisting of ombitasvir/paritaprevir/ritonavir plus dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) has shown high sustained virologic response rates (~95%) in phase 3 clinical trials including >2300 HCV genotype 1-infected patients. Real-world evidence studies have confirmed the effectiveness of OBV/PTV/r ± DSV ± RBV in patients with chronic HCV genotype 1 infection and are consistent with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.